Company Overview and News

Low CPO prices to affect planters’ earnings

Maybank IB Research, which has maintained its “neutral” outlook on the sector, said output recovery in the domestic oil palm sector has failed to compensate for the sharply lower average selling prices of CPO and PK.
Upvote Downvote

Bursa Malaysia bucks regional trend to close easier

2018-04-13 themalaymailonline
KUALA LUMPUR, April 13 — Bursa Malaysia bucked the regional trend to close easier today with the key index snapping its six-day winning streak, weighed by selling in index-linked counters led by MISC, Petronas Chemicals and Astro.
Upvote Downvote

Low stockpile to support CPO price

Strong outlook: There is a potential for CPO to become a substitute for soybean imports, according to analysts. — AFP
Upvote Downvote

Foreign funds step up buying on Bursa Malaysia

KUALA LUMPUR: International investors upped the ante in stocks listed on Bursa despite the nerve-wrecking developments coming from the us, according to MIDF Research.
Upvote Downvote

Mixed fortunes for billionaire owners as stocks struggle to hold gains

KUALA LUMPUR: Billionaire bankers and palm oil planters continue to see their wealth grow year-to-date, as the share price of their flagship companies outperformed the broader stock market rise, fuelled by strong earnings outlook.
Upvote Downvote

KLK net profit lower due to CPO price slump

“The various positive steps taken by Malaysian authorities should limit any further CPO price erosion,” KLK said in a filing with Bursa Malaysia yesterday.
Upvote Downvote

KL Kepong earnings down on lower CPO prices

KUALA LUMPUR: Kuala Lumpur Kepong Bhd (KLK) reported a 11% drop in net profit for the first quarter ended Dec 31, amid slumping price of crude palm oil (CPO) and lower sales volume.
Upvote Downvote

Malaysia’s top 40 richest people

LAST year was dotted by the return of higher commodity prices and better economic growth. The world’s economies on average are back in business as growth rates and trade have started to improve once again after some period of uncertainty caused by a cooling China economy and also the slump in global crude oil prices.
Upvote Downvote

KLK has full MSPO certification for upstream ops

2018-01-19 themalaymailonline
Screengrab of the Kuala Lumpur Kepong Bhd website.KUALA LUMPUR, Jan 19 — Kuala Lumpur Kepong Bhd (KLK) said all its local upstream operations were certified as compliant with Malaysian Sustainable Palm Oil (MSPO) standards at the end of December 2017.
Upvote Downvote

CPO export tax move good for firms with upstream ops

PETALING JAYA: The move to suspend crude palm oil (CPO) export taxes for three months is positive for Malaysian planters as it will help boost exports of the commodity.
Upvote Downvote

KLK finalising acquisition of Dutch chemicals maker

Stable earnings: Given the volatile crude palm oil prices, KLK’s strategy to grow its downstream business could help to mitigate earnings volatility as demand for downstream products is generally more stable.
Upvote Downvote

Trading ideas: Rhone Ma, UEM Sunrise, KLK, Magni-tech

KUALA LUMPUR: JF Apex Research expects Rhone Ma Holdings Berhad, UEM Sunrise Bhd , Kuala Lumpur Kepong Bhd and Magni-Tech Industries Bhd to be among the stocks to watch on Wednesday.
Upvote Downvote

KL Kepong to buy Dutch firm

PETALING JAYA: Kuala Lumpur Kepong Bhd (KL Kepong) is proposing to buy Elementis Specialities Netherlands BV (ESN) in Delden, the Netherlands for �39mil or RM187.2mil.
Upvote Downvote

When the listing comes Sime's plantation and property is a 'must buy'

PETALING JAYA: When the listing of Sime Darby Bhd ’s plantation and property businesses takes place today, Bursa Malaysia should see a hive of activity.
Upvote Downvote

KLK and Batu Kawan post lower earnings, offer DRP to retain cash

KLK says 2018 palm oil production is projected to recover strongly and it expects its plantations’ profit for financial year 2018 to be satisfactory.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 501161202